Table 1 Baseline characteristics, use of organ support and outcome of patients included in the per-protocol analyses
Variable | Active treatment | Placebo treatment |
|---|---|---|
Median (IQR) | Median (IQR) | |
n | 12 | 6 |
Age, years | 61.5 (54.2–68.6) | 71.3 (64.2–75) |
Male gender, n (%) | 8 (66.7%) | 6 (100%) |
BMI, kg/m2 | 24.5 (22.1–28.7) | 27.8 (22.8–30.4) |
Infectious focus | ||
CNS, n (%) | 0 (0%) | 0 (0%) |
Lungs, n (%) | 10 (83.3%) | 4 (66.7%) |
Gastrointestinal, n (%) | 0 (0%) | 2 (33.3%) |
Urogenital, n (%) | 0 (0%) | 0 (0%) |
Skins and soft tissue, n (%) | 2 (16.7%) | 1 (16.7%) |
Blood, n (%) | 0 (0%) | 1 (16.7%) |
Unknown, n (%) | 1 (8.3%) | 0 (0%) |
Identified pathogen (microbiology), n (%) | 9 (75%) | 5 (83.3%) |
Comorbidity | ||
Chronic diagnosis, n (%) | 9 (75%) | 6 (100%) |
Admitted from | ||
Acute medical care unit, n (%) | 6 (50%) | 3 (50%) |
Medical department, n (%) | 3 (25%) | 1 (16.7%) |
Disease severity, physiology and biochemistry | ||
SOFA (first) | 9.0 (7.8–12.0) | 9.5 (7.3–13.3) |
SAPS II | 46 (42–57) | 48 (39–55) |
Systolic blood pressure, mmHg | 113 (100–120) | 123 (104–145) |
Lactate, mmol/l | 1.4 (1.3–3.1) | 3.5 (1.9–3.9) |
pH | 7.35 (7.3–7.41) | 7.41 (7.39–7.41) |
Haemoglobin, mmol/l | 6.9 (6.4–7.7) | 6.5 (5.8–7) |
White blood cell count, × 109/l | 15 (9.8–19.1) | 17.2 (8.8–23.1) |
Platelet count, ×109/l | 188 (130–255) | 212 (149–295) |
INR | 1.2 (1.1–1.2) | 1.3 (1.1–2) |
Antithrombin | 0.64 (0.52–0.76) | 0.58 (0.37–0.82) |
D-dimer | 4.6 (2.4–19.9) | 14.4 (3.4–15.3) |
Creatinine, μmol/l | 97 (67–242) | 126 (114–189) |
Blood urea nitrogen (BUN), mmol/l | 7.9 (5.3–13.2) | 13.5 (8.6–17.9) |
ALAT, U/l | 35 (26–62) | 35 (23–169) |
Bilirubin, μmol/l | 11 (5–24) | 16 (8–29) |
Basic phosphatase, U/l | 64 (57–84) | 149 (76–242) |
C-reactive protein, mg/l | 172 (129–244) | 138 (89–169) |
Therapy and outcome | ||
Ventilator days, n (%) | 5 (3–6) | 6 (4–6) |
Ventilator-free days, n (%) | 25 (24–27) | 24 (6–24) |
RRT days, n (%) | 0 (0–0) | 0 (0–0) |
RRT-free days, n (%) | 30 (29–30) | 30 (8–30) |
Vasopressor days, n (%) | 5 (5–5) | 5 (4–5) |
Vasopressor-free days, n (%) | 25 (24–25) | 25 (6–25) |
Discharged to admitting dept., n (%) | 9 (75%) | 3 (50%) |
Discharged to other hosp., n (%) | 1 (8.3%) | 1 (16.7%) |
Discharged to other ICU, n (%) | 1 (8.3%) | 1 (16.7%) |
Active stop therapy, n (%) | 2 (16.7%) | 1 (16.7%) |
7-day mortality, n (%) | 0 (0%) | 1 (16.7%) |
30-day mortality, n (%) | 1 (8.3%) | 2 (33.3%) |
90-day mortality, n (%) | 3 (25%) | 3 (50%) |